Status:
COMPLETED
Study of the Safety and Efficacy of Desvenlafaxine Succinate for Vasomotor Symptoms in Postmenopausal Women
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Conditions:
Menopause
Vasomotor System
Eligibility:
FEMALE
Phase:
PHASE3
Brief Summary
The purpose of this study is to evaluate the efficacy and safety of 100 mg and 150 mg of DVS SR, an extended release form of desvenlafaxine succinate, in comparison to placebo for the treatment of Vas...
Detailed Description
To assess the efficacy and safety of 100 mg and 150 mg of DVS SR in comparison to placebo for the treatment of moderate to severe VMS associated with menopause, as well as additional outcome indicator...
Eligibility Criteria
Inclusion
- Generally healthy, postmenopausal women who seek treatment for hot flushes
- Body Mass Index (BMI) less than or equal to 40 kg/m2
- Other inclusions apply.
Exclusion
- Hypersensitivity to Venlafaxine
- Myocardial infarction and/or unstable angina within 6 months of screening
- History of seizure disorder
- Other exclusions apply.
Key Trial Info
Start Date :
June 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 1 2007
Estimated Enrollment :
450 Patients enrolled
Trial Details
Trial ID
NCT00369434
Start Date
June 1 2006
End Date
February 1 2007
Last Update
June 1 2007
Active Locations (34)
Enter a location and click search to find clinical trials sorted by distance.
1
Montgomery, Alabama, United States, 36106
2
Peoria, Arizona, United States, 85381
3
Upland, California, United States, 91786
4
Colorado Springs, Colorado, United States, 80910